Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 38.70B | 58x | -1.41 | CHF 535.80 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.5% Upside | Upgrade to Pro+ | |
Lonza Group | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 38.70B | 58x | -1.41 | CHF 535.80 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.5% Upside | Upgrade to Pro+ | |
BACHEM HOLDING AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 4.34B | 38.2x | 2.6 | CHF 57.90 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.9% Upside | Upgrade to Pro+ | |
BB Biotech | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 1.95B | 15.5x | 0.11 | CHF 35.40 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 1.94B | 15.9x | 0.11 | CHF 34.95 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kuros Biosciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 802.18M | -69.7x | -2.98 | CHF 21.35 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Basilea Pharmaceutica AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 501.21M | -766.7x | 7.72 | CHF 41.35 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Newron Pharmaceuticals | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 174.16M | -9.2x | 0.58 | CHF 8.95 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Idorsia | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 153.86M | -0.5x | -0.02 | CHF 0.82 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22% Upside | Upgrade to Pro+ | |
Molecular Partners AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 149.66M | -2.2x | 0.72 | CHF 4.06 | -8.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xlife Sciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 145.84M | 11.8x | 0.38 | CHF 25.40 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 52.80M | -1.1x | -0.02 | CHF 4.21 | -5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Addex Therapeutics Ltd | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 5.62M | 1x | -0 | CHF 0.06 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |